Endometrial Cancer - Pipeline Review, H2 2014


#213600

202pages

Global Markets Direct

$ 2000

In Stock

Endometrial Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Endometrial Cancer - Pipeline Review, H2 2014, provides an overview of the Endometrial Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Endometrial Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Endometrial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Endometrial Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Endometrial Cancer Overview 11
Therapeutics Development 12
Pipeline Products for Endometrial Cancer - Overview 12
Pipeline Products for Endometrial Cancer - Comparative Analysis 13
Endometrial Cancer - Therapeutics under Development by Companies 14
Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes 17
Endometrial Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Endometrial Cancer - Products under Development by Companies 21
Endometrial Cancer - Products under Investigation by Universities/Institutes 23
Endometrial Cancer - Companies Involved in Therapeutics Development 24
Bristol-Myers Squibb Company 24
Sanofi 25
GlaxoSmithKline plc 26
Daiichi Sankyo Company, Limited 27
Merck & Co., Inc. 28
Novartis AG 29
BioMarin Pharmaceutical Inc. 30
Eisai Co., Ltd. 31
ImmunoGen, Inc. 32
Genmab A/S 33
Exelixis, Inc. 34
AEterna Zentaris Inc. 35
Ariad Pharmaceuticals, Inc. 36
Oncothyreon Inc. 37
Critical Outcome Technologies Inc. 38
ArQule, Inc. 39
Galena Biopharma, Inc. 40
Scancell Holdings Plc 41
Oryzon Genomics S.A. 42
Acceleron Pharma, Inc. 43
Arno Therapeutics, Inc. 44
Endocyte, Inc. 45
Esperance Pharmaceuticals, Inc. 46
Pharmsynthez 47
Shenogen Pharma Group Ltd. 48
Igenica Biotherapeutics, Inc. 49
Karyopharm Therapeutics, Inc. 50
OncoHoldings, Inc. 51
Endometrial Cancer - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Combination Products 53
Assessment by Target 54
Assessment by Mechanism of Action 58
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 66
zoptarelin doxorubicin - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ixabepilone - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
lenvatinib - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
MK-2206 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ridaforolimus - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
dalantercept - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
cabozantinib s-malate - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
EP-100 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
dovitinib lactate - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
buparlisib hydrochloride - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
talazoparib - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
GALE-301 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
selinexor - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
cridanimod - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
GSK-2636771 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
OPB-111001 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
SAR-408701 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
CLR-457 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
patritumab - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
HuMax-TF-ADC - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
uprosertib - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
vintafolide - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
ONT-10 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
GSK-2256098 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
trametinib + uprosertib - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
IMGN-853 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Pb-TCMC-Trastuzumab - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
ARQ-092 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
onapristone ER - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
COTI-2 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
EP-200 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
AEZS-125 - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
ONCO-101 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
(ponatinib + ridaforolimus) - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
Peptides to Inhibit GnRH II Receptor for Oncology - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
Antibody Targeting L1CAM for Ovarian and Endometrial Cancer - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
SNG-1153 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
Monoclonal Antibody For Endometrial Cancer - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
Small Molecule to Inhibit AKR1C3 for Oncology - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Small Molecules to Inhibit Ras for Oncology - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
CRC-06 - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
Modi-1 - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
SERD-2 - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
Endometrial Cancer - Recent Pipeline Updates 135
Endometrial Cancer - Dormant Projects 192
Endometrial Cancer - Discontinued Products 193
Endometrial Cancer - Product Development Milestones 194
Featured News & Press Releases 194
Jun 17, 2014: Galena Biopharma Completes Enrollment in GALE-301 Phase 2a Clinical Trial in Ovarian and Endometrial Cancers 194
Jun 02, 2014: Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC Phase 3 Trial in Endometrial Cancer 194
May 22, 2014: Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in Endometrial Cancer with Zoptarelin Doxorubicin at ASCO 195
May 21, 2014: Galena Biopharma to Present GALE-301 Phase 1 Data at the American Society of Clinical Oncology 50th Annual Meeting 195
Feb 04, 2014: Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International Journal of Gynecological Cancer 196
Feb 03, 2014: Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin at Upcoming International Symposium on GnRH 197
Sep 09, 2013: Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors 197
Aug 21, 2013: Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance 198
Jul 31, 2013: Aeterna Zentaris: First Patient Dosed for Phase 3 Registration Trial in Endometrial Cancer with Zoptarelin Doxorubicin 198
Jun 11, 2013: Critical Outcome Technologies Announces Positive Preclinical Results Of Cancer Drug Candidiate COTI-2 Against p53 Gene Mutations 199
Appendix 201
Methodology 201
Coverage 201
Secondary Research 201
Primary Research 201
Expert Panel Validation 201
Contact Us 202
Disclaimer 202

List of Tables
Number of Products under Development for Endometrial Cancer, H2 2014 12
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Late Stage Development, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Development by Companies, H2 2014 (Contd..1) 22
Products under Investigation by Universities/Institutes, H2 2014 23
Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 24
Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 25
Endometrial Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 26
Endometrial Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 27
Endometrial Cancer - Pipeline by Merck & Co., Inc., H2 2014 28
Endometrial Cancer - Pipeline by Novartis AG, H2 2014 29
Endometrial Cancer - Pipeline by BioMarin Pharmaceutical Inc., H2 2014 30
Endometrial Cancer - Pipeline by Eisai Co., Ltd., H2 2014 31
Endometrial Cancer - Pipeline by ImmunoGen, Inc., H2 2014 32
Endometrial Cancer - Pipeline by Genmab A/S, H2 2014 33
Endometrial Cancer - Pipeline by Exelixis, Inc., H2 2014 34
Endometrial Cancer - Pipeline by AEterna Zentaris Inc., H2 2014 35
Endometrial Cancer - Pipeline by Ariad Pharmaceuticals, Inc., H2 2014 36
Endometrial Cancer - Pipeline by Oncothyreon Inc., H2 2014 37
Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2014 38
Endometrial Cancer - Pipeline by ArQule, Inc., H2 2014 39
Endometrial Cancer - Pipeline by Galena Biopharma, Inc., H2 2014 40
Endometrial Cancer - Pipeline by Scancell Holdings Plc, H2 2014 41
Endometrial Cancer - Pipeline by Oryzon Genomics S.A., H2 2014 42
Endometrial Cancer - Pipeline by Acceleron Pharma, Inc., H2 2014 43
Endometrial Cancer - Pipeline by Arno Therapeutics, Inc., H2 2014 44
Endometrial Cancer - Pipeline by Endocyte, Inc., H2 2014 45
Endometrial Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2014 46
Endometrial Cancer - Pipeline by Pharmsynthez, H2 2014 47
Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd., H2 2014 48
Endometrial Cancer - Pipeline by Igenica Biotherapeutics, Inc., H2 2014 49
Endometrial Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 50
Endometrial Cancer - Pipeline by OncoHoldings, Inc., H2 2014 51
Assessment by Monotherapy Products, H2 2014 52
Assessment by Combination Products, H2 2014 53
Number of Products by Stage and Target, H2 2014 56
Number of Products by Stage and Mechanism of Action, H2 2014 60
Number of Products by Stage and Route of Administration, H2 2014 63
Number of Products by Stage and Molecule Type, H2 2014 65
Endometrial Cancer Therapeutics - Recent Pipeline Updates, H2 2014 135
Endometrial Cancer - Dormant Projects, H2 2014 192
Endometrial Cancer - Discontinued Products, H2 2014 193

List of Figures
Number of Products under Development for Endometrial Cancer, H2 2014 12
Number of Products under Development for Endometrial Cancer - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 14
Number of Products under Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Products, H2 2014 20
Assessment by Monotherapy Products, H2 2014 52
Assessment by Combination Products, H2 2014 53
Number of Products by Top 10 Target, H2 2014 54
Number of Products by Stage and Top 10 Target, H2 2014 55
Number of Products by Top 10 Mechanism of Action, H2 2014 58
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 59
Number of Products by Top 10 Route of Administration, H2 2014 62
Number of Products by Stage and Top 10 Route of Administration, H2 2014 63
Number of Products by Top 10 Molecule Type, H2 2014 64
Number of Products by Stage and Top 10 Molecule Type, H2 2014 65